Amaçlar: Bu çalışmanın amacı, diyabetik nefropatili sıçanların böbrek dokusunda oksidatif stres ve 8-hidroksideoksiguanozin'i (8-OHdG) hedef alarak, morin hidratın tek başına veya metformin ile birlikte kullanımının diyabetik nefropatiye karşı koruyucu etkisini araştırmaktır.
Metotlar: Bu deneysel çalışmada, sıçanlara streptozotosin (STZ) enjeksiyonu ile diyabetik nefropati oluşturuldu. Morin hidratın diyabetik nefropatiyi inhibe etme yeteneği, biyokimyasal, immünohistokimyasal ve immünofloresan yöntemleri kullanılarak böbrek dokularında oksidatif stres parametreleri olan lipid peroksidasyonu (LPO), glutatyon, glutatyon peroksidaz, süperoksit dismutaz ve katalaz; DNA hasar belirteci olan 8-OHdG; böbrek hasarı belirteci olan kidney injury molekül-1 (KIM-1) ve aquaporin; ve serum örneklerinde böbrek fonksiyonunun belirteçleri olan kreatinin ve kan üre azotunu ölçümü ile test edildi.
Bulgular: STZ uygulamasından sonra LPO, 8-OHdG, KIM-1 ve aquaporin düzeylerinde anlamlı artışlar (p < 0.0001) ve glutatyon, glutatyon peroksidaz, süperoksit dismutaz ve katalaz düzeylerinde anlamlı düşüşler (p < 0.0001) gözlemlenmiştir. Bu da diyabetik nefropatinin geliştiğini ve ilerlediğini göstermektedir. Morin hidrat ile tedavi, özellikle metformin ile birlikte uygulandığında oksidan düzeylerini baskıladığı, antioksidan sistemi ve böbreğin histolojik yapı bütünlüğünü iyileştirdiği gözlenmiştir. Bu durumun KIM-1 ve aquaporin düzeylerine ve böbrek fonksiyon belirteçlerine olumlu olarak yansıdığı görülmüştür.
Sonuç: Morin hidrat, böbrek dokularında oksidatif stresi ve 8-OHdG düzeylerini baskılayarak diyabetes mellitus kaynaklı diyabetik nefropatiyi önler. Bu nedenle, bu biyoflavonoid, diyabetik nefropatisi olan hastalar için umut verici bir adaydır. Ayrıca, morin hidrat-metformin kombinasyon tedavisi, tek başına uygulanan tedaviye göre daha iyi bir etkinlik sağlamış olup, bu da morin hidrat ve metforminin diyabetik nefropatili hastaların tedavisinde önemli bir sinerjik rol oynayacağını ifade etmektedir.
TÜBİTAK 2209-A (Project ID: 1919B012222415)
Aims: The aim of this study was to investigate the protective effect of morin hydrate either individually or in combination with metformin against diabetic nephropathy by targeting oxidative stress and 8-hydroxydeoxyguanosine (8-OHdG) in the kidney tissue of rats with diabetic nephropathy.
Methods: In this experimental study, diabetic nephropathy was induced in rats by injection of streptozotocin (STZ). The ability of morin hydrate to inhibit diabetic nephropathy was tested by screening lipid peroxidation (LPO), glutathione, glutathione peroxidase, superoxide dismutase, and catalase as parameters of oxidative stress; 8-OHdG as a marker of DNA damage and kidney injury molecule-1 (KIM-1) and aquaporin as indicators of kidney injury in renal tissues; and serum creatinine and blood urea nitrogen as markers of renal function using biochemical, immunohistochemical, and immunofluorescence methods.
Results: Significant increases (p<0.0001) in LPO, 8-OHdG, KIM-1, and aquaporin levels and significant decreases (p<0.0001) in glutathione, glutathione peroxidase, superoxide dismutase, and catalase levels were observed after STZ administration, indicating the development and progression of diabetic nephropathy. Treatment with morin hydrate, especially in combination with metformin, suppressed the oxidant levels and improved the antioxidant system and the histopathological integrity of the kidney, which was positively reflected in the levels of KIM-1, aquaporin, and kidney function parameters.
Conclusion: Morin hydrate prevents diabetic nephropathy resulting from diabetes mellitus by suppressing oxidative stress and 8-OHdG levels in kidney tissues. Therefore, this bioflavonoid represents a promising candidate for patients with diabetic nephropathy. Moreover, the combination therapy of morin hydrate and metformin achieved better effectiveness than the single treatment, which emphasizes an important synergistic role of morin hydrate and metformin in managing patients with diabetic nephropathy.
Ethical approval was obtained from the Ethics Committee of Animal Experiments at Ataturk University (Decision No: 292, Date: 22.12.2022).
TÜBİTAK
TÜBİTAK 2209-A (Project ID: 1919B012222415)
This study was supported by TÜBİTAK 2209-A (Project ID: 1919B012222415).
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Biochemistry, Pathology, Medical Biochemistry and Metabolomics (Other) |
| Journal Section | Research Articles |
| Authors | |
| Project Number | TÜBİTAK 2209-A (Project ID: 1919B012222415) |
| Publication Date | October 26, 2025 |
| Submission Date | August 6, 2025 |
| Acceptance Date | September 23, 2025 |
| Published in Issue | Year 2025 Volume: 7 Issue: 6 |
TR DİZİN ULAKBİM and International Indexes (1b)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show
Journal Indexes and Platforms:
TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.The indexes of the journal's are;
The platforms of the journal's are;
|
The indexes/platforms of the journal are;
TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit
Journal articles are evaluated as "Double-Blind Peer Review"
All articles published in this journal are licensed under a Creative Commons Attribution 4.0 International License (CC BY NC ND)